All news

Under a Nov. 16 deal, 2,466,395 Arcturus Therapeutics (ARCT) shares are issuable to Meiji Seika Pharma.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Meiji Seika Pharma Co., Ltd. has reported a 7.88% passive stake in Arcturus Therapeutics Holdings Inc. (ARCT), comprising 2,466,395 shares. This ownership percentage is based on 28,822,514 shares outstanding as of November 3, 2026, plus the shares issuable under a Securities Purchase Agreement dated November 16, 2026. Meiji Seika Pharma holds sole voting and dispositive power over these shares.

Read original source

ARCT company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.